Table 1.
Relevant clinical characteristics of patients.
| Patient | Date of Isolation | Age (Years) | Gender | Comorbidities | Site of Infection | Treatment | Death (Yes/No) | MIC * (µg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEM | DOR | CAZ | TZP | GEN | CIP | SXT | CST | ||||||||
| 1 | 8 April 2017 | 66 | Male | None | Abdomen | Colistimethate + Doripenem | Yes | 1024 | 512 | >256 | >512 | >256 | 32 | >256 | 0.5 |
| 2 | 25 March 2017 | 56 | Male | Polytrauma | Bone | Colistimethate + Doripenem + Rifampin | No | 1024 | 512 | >256 | >512 | >256 | 16 | >256 | 0.5 |
| 3 | 18 April 2017 | 84 | Female | Total hip replacement | Bone | Colistimethate + Doripenem + Rifampin | Yes | 1024 | 512 | >256 | >512 | >256 | 32 | >256 | 0.5 |
| 4 | 22 April 2017 | 57 | Male | Benign prostatic hyperplasia | Blood | Colistimethate + Doripenem | No | 1024 | 512 | >256 | >512 | >256 | 32 | >256 | 0.5 |
| 5 | 12 July 2017 | 29 | Male | Epilepsy, Down Syndrome | Urine | Colistimethate + Doripenem + Fosfomycin | Yes | 1024 | 512 | >256 | >512 | >256 | 32 | >256 | 0.5 |
| MIC of ATCC27853 | - | 0.25 | 0.12 | 4 | 4 | 1 | 0.12 | 16 | 0.5 | ||||||
* MEM, meropenem; DOR, doripenem; CAZ, ceftazidime; TZP, piperacillin-tazobactam; GEN, gentamicin; CIP, ciprofloxacin; SXT, trimethoprim/sulfamethoxazole; and CST, colistin.